CLNN Clene Inc.

Clene is revolutionizing the treatment of neurodegenerative disease with an innovative nanotherapeutic platform to generate first-in-class elemental nanomedicines designed to optimize neurorepair and health through energy-enhancing bioenergetic catalysis.

As of 09/28/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/27/2018
Outstanding shares:  63,501,984
Average volume:  197,637
Market cap:   $185,425,793
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMW2FV3
Valuation   (See tab for details)
PE ratio:   11.13
PB ratio:   91.25
PS ratio:   931.79
Return on equity:   1,488.15%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy